PenderFund Capital Management
CLDI icon

PenderFund Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

PenderFund Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35
Closed -$922K – 110
2023
Q2 		$922K Hold
35
– – 0.29% 56
2023
Q1 		$921K Buy
35
+7
+25% +$137K 0.29% 58
2022
Q4 		$731K Buy
+28
New +$537K 0.22% 63

Other funds holding CLDI

Meteora Capital
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
Finepoint Capital
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Spectrum Asset Management (California)
Spectrum Asset Management (California) Newport Beach, California $346M AUM 13.82% 1-Year Est. Return
Red Wave Investments
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
Delta Investment Management
Delta Investment Management San Francisco, California $608M AUM 25.3% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

PenderFund Capital Management's CLDI Position: Q3 2023 in Review

PenderFund Capital Management sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 35 shares — an estimated $922K sold.

PenderFund Capital Management first reported a position in CLDI in Q4 2022 and held it in 3 quarters. The position peaked at $922K in Q2 2023. 10 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • PenderFund Capital Management reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • PenderFund Capital Management sold 35 Calidi Biotherapeutics shares in Q3 2023, an estimated $922K.
  • PenderFund Capital Management first reported a position in Calidi Biotherapeutics in Q4 2022 and held it in 3 quarters.
  • PenderFund Capital Management's Calidi Biotherapeutics position peaked at $922K in Q2 2023.
  • 10 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on PenderFund Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.